Skip to main content
Signal8

MANGOCEUTICALS, INC. (MGRX)

Mangoceuticals, Inc. dedicates its operations to the creation, promotion, and distribution of a variety of health and wellness products and services specifically designed for men. These offerings are primarily delivered through a telemedicine platform. The company's product line includes treatments for erectile dysfunction, marketed under the 'Mango' brand. Consumers can purchase these items directly from its official online portal, mangorx.com. Established in 2021, Mangoceuticals, Inc. is headquartered in Dallas, Texas, and operates as an affiliate of Cohen Enterprises, Inc.

Sector: Services-Misc Health & Allied Services, NEC

Industry: Medical - Healthcare Information Services

Mangoceuticals, Inc. logo

Mangoceuticals, Inc.

NASDAQ:MGRXHealthcare
-0.19%$0.1600
CLOSED
AH$0.1654+3.38%vs close
Mkt Cap$3.56M
EV$2.38M
Float17.27M
O/S22.22M
VOL409K sh
$ Vol$65K
RVOL0.52×
Inst Own7.5%
SI0.3%
Net Cash/Sh+$0.05
Dilution
Mangoceuticals, Inc. logoNASDAQ:MGRXClosed$0.1600-0.19%
Financials Summary
Revenue$456K
Net Income-$20.64M
Total Assets$16.09M
Free Cash Flow-$5.85M
Debt & Equity
Debt 2%
Equity 98%
Preferred 0%
Total Debt$308K
Total Equity$15.2M
Preferred Stock$98
Shares Outstanding
Short Interest

No short interest data available.

Split History1 split · 1 reverse
  1. 1:15Reverse split
    Oct 16, 202415 shares → 1
Balance Sheet Details
Assets$16.09M
Liabilities$891K
Accounts Receivable$0
Accounts Payable$417K
Inventory$0
PP&E (Net)$310K
Goodwill$0
Intangible Assets$14.23M
Income Statement
PeriodFY 2025FY 2024FY 2023FY 2022FY 2021
CurrencyUSDUSDUSDUSDUSD
Period Ending2025-12-312024-12-312023-12-312022-12-312021-12-31
Revenue$456K$616K$731K$9K$0
YoY Growth-26.0%-15.8%8083.2%--
Cost of Revenue$206K$236K$300K$4K$0
Gross Profit$250K$380K$432K$5K$0
Gross Margin54.9%61.7%59.0%54.3%-
Research and Development$0$0$0$0$0
Selling, General, and Administrative$16.72M$7.9M$5.42M$2M$18K
Other$2.68M$454K$4.23M$0$0
Total Operating Expenses$19.41M$8.35M$9.65M$2M$18K
Operating Income (EBIT)-$19.15M-$7.97M-$9.22M-$1.99M-$18K
Operating Margin-4200.5%-1294.4%-1260.3%-22279.7%-
Interest Expense$104K$14K$0$6K$181
Interest Income$0$0$6K$0$0
Other Income (Expense)-$1.49M-$735K$6K-$6K-$181
Income Before Tax (EBT)-$20.64M-$8.71M-$9.21M-$2M-$18K
Income Tax Expense$0$0$0$0$0
Net Income-$20.64M-$8.71M-$9.21M-$2M-$18K
Net Income Margin-4526.9%-1413.6%-1259.4%-22352.1%-
Supplementary Data
EPS-2.17-4.40-6.45-1.73-0.02
Diluted EPS-2.17-4.40-6.45-1.73-0.02
Weighted Average OS10.07M1.98M1.43M1.15M1.15M
EBITDA-$18.82M-$7.96M-$8.09M-$1.99M-$18K
EBITDA Margin-4126.1%-1292.9%-1106.4%-22236.5%-
Balance Sheet
PeriodFY 2025FY 2024FY 2023FY 2022FY 2021
CurrencyUSDUSDUSDUSDUSD
Period Ending2025-12-312024-12-312023-12-312022-12-312021-12-31
Assets
Current Assets
Cash and Cash Equivalents$1.49M$59K$739K$683K$23K
Short-Term Investments$0$0$0$0$0
Cash and Short-Term Investments$1.49M$59K$739K$683K$23K
Accounts Receivable$0$0$0$0$0
Inventory$0$0$19K$0$0
Other Current Assets$61K$17K$0$0$0
Total Current Assets$1.55M$76K$818K$695K$23K
Long-Term Assets
Property, Plant & Equipment Net$310K$62K$215K$292K$0
Goodwill$0$0$0$0$0
Intangible Assets$14.23M$15.23M$0$0$0
Long-Term Investments$0$0$0$0$0
Deferred Tax Assets$0$0$0$0$0
Other Long-Term Assets$0$0$17K$17K$0
Total Long-Term Assets$14.54M$15.29M$232K$309K$0
Other Assets$0$0$0$0$0
Total Assets$16.09M$15.37M$1.05M$1M$23K
Liabilities
Current Liabilities
Accounts Payable$417K$838K$141K$34K$0
Short-Term Debt$0$150K$0$167K$39K
Current Income Tax Payable$0$0$7K$3K$0
Current Unearned Revenue$0$0$0$0$0
Other Current Liabilities$0$373K$0$0$0
Total Current Liabilities$891K$1.43M$211K$261K$39K
Long-Term Liabilities
Long-Term Debt$0$0$0$0$0
Long-Term Unearned Revenue$0$0$0$0$0
Long-Term Deferred Tax Liabilities$0$0$0$0$0
Other Long-Term Liabilities$0$0$0$0$0
Total Long-Term Liabilities$0$0$65K$129K$0
Other Liabilities$0$0$0$0$0
Total Liabilities$891K$1.43M$276K$389K$39K
Stockholders' Equity
Preferred Stock$98$98$0$0$0
Common Stock$2K$325$2K$1K$800
Retained Earnings-$40.65M-$20.81M-$11.23M-$2.02M-$18K
Comprehensive Income & Other-$3K-$10K$0$0$0
Other Stockholders' Equity$55.85M$34.75M$12M$2.63M$181
Total Equity$15.2M$13.95M$775K$614K-$17K
Minority Interest-$2K-$1K$0$0$0
Total Liabilities and Equity$16.09M$15.37M$1.05M$1M$23K
Supplementary Data
Total Debt$308K$215K$129K$353K$39K
Net Debt-$1.18M$156K-$610K-$330K$17K
Cash Flow Statement
PeriodFY 2025FY 2024FY 2023FY 2022FY 2021
CurrencyUSDUSDUSDUSDUSD
Period Ending2025-12-312024-12-312023-12-312022-12-312021-12-31
Operating Activities
Net Income-$20.64M-$8.71M-$9.21M-$2M-$18K
Depreciation & Amortization$1.72M$731K$25K$4K$0
Deferred Income Tax$0$0$0-$152K$0
Stock-Based Compensation$1.17M$249K$624K$234K$0
Changes in Working Capital:
  Accounts Receivable-$20K$0$0$0$0
  Inventory$0$0$0$0$0
  Accounts Payable$56K$697K$107K$34K$0
  Other Working Capital$935K-$36K-$66K-$15K$0
Total Working Capital Change$970K$660K$42K$19K$0
Other Non-Cash Items$10.93M$2.2M$1.52M$547K$181
Net Cash from Operating-$5.85M-$4.86M-$7M-$1.35M-$18K
Investing Activities
Capital Expenditures$0$0-$4K-$43K$0
Acquisitions$0$0$0$0$0
Purchases of Investments$0$0$0$0$0
Sales of Investments$0$0$0$0$0
Other Investing Activities$0$65K$0$0$0
Net Cash from Investing$0$65K-$4K-$43K$0
Financing Activities
Debt Repaid$207K----
Common Stock Issuance$5.65M$1.33M$6.2M$2M$800
Common Stock Repurchases$0$0$0$0$0
Dividends Paid$0-$802K$0$0$0
Other Financing Activities$1.15M$802K$1.02M$0$0
Net Cash from Financing$7.27M$4.13M$7.06M$2.05M$40K
Forex Effect$7K-$10K$0$0$0
Net Change in Cash$1.43M-$680K$56K$660K$23K
Supplementary Data
Operating Cash Flow-$5.85M-$4.86M-$7M-$1.35M-$18K
Capital Expenditure-$5$0-$4K-$43K$0
Free Cash Flow-$5.85M-$4.86M-$7M-$1.39M-$18K
Cash at Beginning$59K$739K$683K$23K$0
Cash at End$1.49M$59K$739K$683K$23K